MoonLake Immunotherapeutics remains a promising clinical-stage biotech, with potentially its first FDA approval in 2026.

Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 ...

MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the 10 Stocks with Huge Catalysts on the Horizon. The company speeds up ...

ZUG, Switzerland, May 12, 2025 – MoonLake Immunotherapeutics (MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for ...

MoonLake Immunotherap is still within a buying range after moving past a 52.88 buy point in a cup with handle. Once a stock moves 5% or higher beyond the original entry, it's considered out of buy ...

MoonLake also anticipates sharing an interim read out from the Phase 2 LEDA trial of sonelokimab in palmoplantar pustulosis (PPP), the first clinical trial in PPP for an IL-17A and IL-17F inhibitor.

US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion. While MoonLake turned down the initial offer ...

MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of -30.18 and a beta of 1.31.

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter ...

In trading on Tuesday, shares of MoonLake Immunotherapeutics (Symbol: MLTX) entered into oversold territory, hitting an RSI reading of 28.1, after changing hands as low as $32.38 per share.

MoonLake Immunotherapeutics’ lead development asset sonelokimab is a novel investigational Nanobody for inflammatory diseases. Also Read: Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers ...